Qianru Hong


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Qianru Hong is an associate in O’Melveny’s Shanghai office. She has participated in projects covering investigation / compliance, merger and acquisition, private equity/venture capital investment, investigations, capital markets, intellectual property, employment, foreign direct investment and general corporate matters, in industries covering energy, finance, internet, e-commerce and media.

Prior to joining the firm, Qianru interned with a US law firm, a Hong Kong law firm and a Chinese domestic law firm.


  • Mandarin Chinese
  • English


  • Columbia Law School, LL.M., James Kent Scholar
  • Fudan University, LL.M.
  • Shanghai International Studies University, LL.B.; B.A.

Professional Activities

Bar Exam

  • Passed Chinese Bar Exam
  • RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
  • A buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group in a “going private” transaction valued at approximately US$380 million
  • Participated in and assisted various venture capital deals including representations of internationally recognized venture capital funds and start-up or pre-IPO companies
  • Assisted a U.S. public REIT in setting up an equity investment fund in Shanghai
  • Assisted a U.S. coal technology company’s financing and its foreign direct investment in China
  • Assisted an Asian private equity fund in its acquisition of office buildings in China
  • Assisted a biopharmaceutical company’s spin-off and follow-up financing
  • Assisted a Swedish security lock company in its acquisition of a well-known Chinese fingerprint lock company
  • Assisted a U.S. floor manufacturer in its acquisition of its Chinese partners interest in their China joint venture
  • Assisted in advising small-loan companies in Chongqing in their loan transactions and with respect to PRC finance laws and regulations
  • Assisted in advising a leading high-tech company in its dismantling of the red-chip structure and the proposed IPO in China
  • Assisted in representing several companies in its proposed IPO in the U.S. and Hong Kong
  • Assisted in several deals representing multinational corporations establishing joint ventures, wholly foreign owned enterprises, representative offices and branch companies in China
  • Assisted in dealing with the general corporate matters of multinational companies’ subsidiaries in China